Skip to main content

Hepatitis C clinical trials at UCSF

4 in progress, 3 open to eligible people

Hepatitis C is an illness that affects the liver. UCSF is working on research to find risk factors in adults with liver cirrhosis. One trial compares a drug called rosuvastatin with a placebo to check its safety for people with cirrhosis. UCSF is also studying hepatitis C treatment options for young people who inject drugs.

Showing trials for
  • Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

    open to eligible people ages 18-75

    This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

    San Francisco, California and other locations

  • Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs

    open to eligible people ages 18 years and up

    The Partner Navigation Intervention Study is a randomized controlled study (RCT) to assess the efficacy and mechanism of action of the first behavioral intervention to increase hepatitis C (HCV) treatment initiation among adult people who inject drugs (PWID).

    San Francisco, California

  • Liver Cirrhosis Network Cohort Study

    open to eligible people ages 18 years and up

    Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.

    San Francisco, California and other locations

  • Insulin Resistance in HCV Infection

    Sorry, in progress, not accepting new patients

    The study hypothesis is that the means by which HCV induces glucose intolerance is through impairment of B-cell function and compensatory hyperinsulinemia in predisposed Latinos with insulin resistance and that HCV eradication improves these abnormalities. It is also hypothesized that moderate alcohol consumption impact insulin sensitivity and secretion with Latinos with or without HCV infection.

    San Francisco, California

Our lead scientists for Hepatitis C research studies include .

Last updated: